Comparative Pharmacology
Head-to-head clinical analysis: BETAGAN versus TRANDATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAGAN versus TRANDATE.
BETAGAN vs TRANDATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-1 selective beta-adrenergic receptor antagonist; reduces intraocular pressure by decreasing aqueous humor production.
Competitive antagonist at beta-1 and beta-2 adrenergic receptors; also blocks alpha-1 adrenergic receptors, causing vasodilation.
Instill 1 drop of 0.25% or 0.5% solution into the affected eye(s) twice daily.
Initial: 100 mg orally twice daily, titrate to 200-400 mg twice daily; maximum 2400 mg/day. Alternatively, 20 mg IV bolus over 2 minutes, then 40-80 mg IV at 10-minute intervals as needed; IV infusion: 2 mg/min, titrate to response.
None Documented
None Documented
Terminal elimination half-life is approximately 10-15 hours in adults; prolonged in renal impairment (up to 30 hours).
Terminal elimination half-life is approximately 6-8 hours in healthy individuals, but may be prolonged in patients with hepatic impairment or severe renal dysfunction (up to 12-16 hours).
Primarily renal excretion of unchanged drug and metabolites; about 80% eliminated in urine, 20% in feces as unchanged drug or glucuronide conjugates.
Labetalol is extensively metabolized in the liver via glucuronidation; less than 5% of the dose is excreted unchanged in urine. Approximately 55-60% of metabolites are excreted renally, and about 30% in feces via biliary secretion.
Category C
Category C
Beta-Blocker
Beta-Blocker